The recent decision by the DEA to reclassify cannabis as a Schedule III substance has sparked a range of reactions within the cannabis industry. While many see this as a positive step towards acknowledging the plant’s potential benefits, others are wary of the implications of such a move.
Public opinion has undoubtedly played a significant role in this decision. As attitudes towards cannabis continue to evolve, so do the regulations surrounding it. The shifting perceptions towards cannabis, from being viewed as a dangerous drug to one with potential health and wellness benefits, have led to this reclassification away from Schedule I, a category reserved for the most dangerous drugs.
Jack Blaeser, founder of Mosaic, a company that empowers dispensaries, sees this shift as a positive development. He believes that this reclassification will help dispensaries meet the changing demands of customers, facilitating a smoother transition into a new era of cannabis acceptance and accessibility.
However, not everyone shares Blaeser’s optimism. Dr. Neha Raje, co-founder of Oneness Technologies, a cannabis biotech company, believes that this decision could pave the way for pharmaceutical companies to take over the cannabis industry. “Rescheduling to Schedule III means that cannabis will still be regulated by the DEA, 
and only pharmaceutical companies have the necessary infrastructure to operate under that category,” says Dr. Raje.
Despite concerns about the potential dominance of pharmaceutical companies, some within the industry remain cautiously optimistic about the reclassification. Chris Piazza, founder of CannaDevices, acknowledges the progress but also points out the challenges ahead. “When rescheduling occurs, the industry will have a revitalization as the unfair financial burdens of taxation, banking restrictions, and predatory lending will be things of the past,” says Piazza. “But we will get new hurdles like increased oversight on our cultivation/processing from what I understand.”
The agreement on the reclassification reflects a changing mindset towards cannabis within the country. However, there is a consensus 
among industry insiders that while this decision is a step in the right direction, there is still much progress to be made.
“Overall, it’s great headline news,” says Piazza, “but now we’re waiting for the substance of the actual signatures to make these changes official.”
The reclassification of cannabis by the DEA represents a significant milestone in the evolving landscape of cannabis regulation. While it may open doors for the industry, there are also challenges and uncertainties that lie ahead. Only time will tell how this decision will shape the future of the cannabis industry in the United States.
